Tysabri labeling changes submitted to help stratify PML risk
Tysabri labeling changes submitted to help stratify PML risk
Biogen Idec and Elan Corporation, plc have announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective Tysabri Prescribing Information and Summary of Product Characteristics.
The companies are proposing updated product labeling to include anti-JC Virus antibody status as one potential factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, in the Tysabri-treated population.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2198 Views
-
Last post by NHE
-
- 6 Replies
- 5183 Views
-
Last post by ElliotB
-
- 0 Replies
- 1284 Views
-
Last post by NHE
-
- 0 Replies
- 1574 Views
-
Last post by NHE
-
- 0 Replies
- 3275 Views
-
Last post by NHE
-
- 1 Replies
- 980 Views
-
Last post by NHE
-
- 11 Replies
- 3246 Views
-
Last post by NHE
-
- 1 Replies
- 1445 Views
-
Last post by NHE
-
- 0 Replies
- 3057 Views
-
Last post by NHE